

November 14, 2022

National Stock Exchange of India Limited,
Listing Department
Exchange Plaza, 5th Floor,
Bandra (E), Mumbai-400051

BSE Limited
Listing Department Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHIDPHARMA**

Scrip Code: **524372**

Subject: Press Release – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 read with Schedule III SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the press release on Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and the Half Year ended September 30, 2022.

These are also being made available on the official website of the Company i.e. www.orchidpharma.com

You are requested to take the above on record.

Thanking You,
For **Orchid Pharma Limited**



Manish Dhanuka
Managing Director
DIN: 00238798



Orchid Pharma reports positive EBIDTA in Q2' 2022

- Revenue jumps 36% on Q-o-Q basis and 36% over the last one year
- EBITDA jumps 154% on Q-o-Q basis and 133% over the last one year
- Post a successful turnaround of IBC case, the company continues its march towards growth and sustainability


New Delhi, 14th November 2022: Orchid Pharma today announced their Q2'22 results. Fuelled by increasing sales and a laser sharp focus on costs, Orchid Pharma reported a 36% surge in total revenue from operations while the EBIDTA has jumped by 104% over the quarter ending September 2021.

Dhanuka Group, through its pharmaceutical arm, Dhanuka Laboratories Ltd, had taken over the company through the CIRP (Corporate Insolvency Resolution Process) on 31st March 2020. In spite of the COVID-19 Pandemic, the group through its relentless efforts has turned around the business and within a year made the loss-making business profitable.


Results highlights are as below:

Progress of Turnaround

Revenues



EBITDA



■ Before takeover
■ After takeover
All Figures in Cr.

Speaking on the Q2 results, **Manish Dhanuka, Managing Director, Orchid Pharma** said, *“Our revenues have seen a sharp uptick over the last one year. We have focussed on increasing the capacity utilizations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come.”*

In the near future, the implementation of the PLI project of 7-ACA will lead to more comprehensive backward integration of Orchid's supply chain. A robust product launch

pipeline in tandem with all the other significant steps we are taking, is set to make Orchid an even stronger player in the Cephalosporin Antibiotics space in the world.

Orchid Pharma Limited.

Established in 1992 as an export-oriented unit (EOU), [Orchid Pharma Ltd.](#) (Orchid) is a vertically integrated company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing.

Orchid, is the only Indian Pharmaceutical Company, to ever have invented a New Chemical Entity (NCE, also colloquially called New Drug) which has cleared Global Clinical Trials of Phase III. The molecule is out licensed (on Royalty model) and now under worldwide New Drug Approval Process.

Orchid is a pioneer in Production of Quality Cephalosporins especially the Sterile Products, for which it is the one out of the only three USFDA approved facilities in the world, and the only one from India. Besides this, the facility has other approvals like EU GMP, ANVISA and PMDA.

Dhanuka Group acquired Orchid Pharma Ltd. through CIRP (Corporate Insolvency Resolution Process) under IBC (Indian Bankruptcy Code) on 31st March 2020. Since, then the company has gone through a dramatic transformation going from a negative EBIDTA to healthy positive numbers.